The Role of lncRNA PCAT6 in Cancers

Wang, Siying; Chen, Zhenyao; Gu, Jianqin; Chen, Xin; Wang, Zhaoxia

doi:10.3389/fonc.2021.701495

Cited by 16 publications

(13 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on single factor Cox regression and Lasso-Cox analysis, nine LNC RNAs (PCAT6, LINC00858, LINC01234, FGF14-AS2, FAM83C-AS1, HOTAIR, MIR31HG, DDX11-AS1, and ELFN1-AS1) were identified as being closely related to patient prognosis. PCAT6 was found to be highly expressed in colon cancer by Wang et al [20] and to play an important role in the clinical evaluation of colon cancer. In colon cancer, LINC00858 can function as LNC RNA [21].…”

Section: Drug Sensitivity Analysis Of Risk Modelmentioning

confidence: 97%

Explore the prognostic characteristics of immunogenic cell death- related genes in colon carcinoma based on multi-constraint canonical correlation analysis

Xiong

Cao

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

The prognosis for colon carcinoma is poor, it is a highly aggressive tumor, and its early symptoms are subtle. Hence, the need for more colon cancer prognostic indicators is urgent. Many long non-coding RNAs (lncRNAs) are known to actively contribute to the detection, prognosis, and treatment of tumors. On the other hand, immunogenic cell death (ICD) is vital for the prevention of tumors. This study seeks to research the mechanism of action of ICD-related lncRNAs in colon cancer and integrate ICD-related genes with lncRNAs. In order to investigate ICD-related lncRNAs, this research suggests a multi-constraint canonical correlation analysis. The prognostic model of the most significant lncRNAs is also constructed and verified in this paper using univariate and Lasso-Cox regression. In this study, colon cancer samples are split into high-risk and low-risk groups based on the model's risk score, and the impact of the model is assessed using the TCGA queue and the GEO queue, respectively. Also, we thoroughly examined the parallels and discrepancies in immune infiltration, functional enrichment, and medication sensitivity across the two risk groups. In conclusion, the ICD-related lncRNAs risk model developed in this research can serve as a guide for predicting the prognosis and therapeutic sensitivity of colon cancer patients.

show abstract

Section: Drug Sensitivity Analysis Of Risk Modelmentioning

confidence: 97%

Explore the prognostic characteristics of immunogenic cell death- related genes in colon carcinoma based on multi-constraint canonical correlation analysis

Xiong

Cao

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In prostate tumor cells, this lncRNA was shown to induce colony formation and keratinocyte proliferation [9]. Its upregulation has also been reported in a variety of tumors including bladder, ovarian, lung, and gastric cancers, as well as in osteosarcoma, hepatocellular carcinoma (HCC), and glioblastoma [10]. PCAT6 can increase the proliferative, migratory, and angiogenic activity of triplenegative breast cancer (TNBC) cells in vitro and in vivo, and VEGF derived from M2 macrophages can stimulate PCAT6 upregulation to promote angiogenic activity in the context of TNBC [11].…”

Section: Introductionmentioning

confidence: 98%

LncRNA PCAT6 as a Predictor of Poor Colorectal Cancer Patient Prognosis: A TCGA Dataset Analysis

Lin

Sun²,

Sun³

2021

Preprint

View full text Add to dashboard Cite

Background: The long non-coding RNA (lncRNA)) PCAT6 has been studied in many cancers, yet its relationship with colorectal cancer (CRC) remains poorly defined. Here, we conducted an analysis of The Cancer Genome Atlas (TCGA) database to better clarify the role of PCAT6 in this cancer type.Materials and Methods: Wilcoxon rank-sum tests were utilized to assess relative levels of PCAT6 in CRC tumors and normal tissues, while logistic regression analyses were utilized to compare the relationships between PCAT6 levels and clinicopathological findings. Kaplan-Meier curves and Cox regression analyses were used to gauge correlations between PCAT6 and patient survival outcomes, while the biological roles of this lncRNA were investigated via a gene set enrichment analysis (GSEA) approach.Results: PCAT6 levels were significantly correlated with CRC patient N stage (OR = 1.8 for N1&N2 vs. N0), lymphatic invasion (OR = 1.9 for Yes vs. No), M stage (OR = 2.1 for M1 vs. M0), CEA level (OR = 1.9 for >5 vs. ≤5), perineural invasion (OR = 1.9 for Yes vs. No), pathologic stage (OR = 1.9 for Stage IIIIV vs. Stage I/II), and neoplasm type (OR = 2.1 for rectal adenocarcinoma vs. colon adenocarcinoma) (all P < 0.05). CRC patients expressing higher PCAT6 levels exhibited poorer survival outcomes than those expressing low levels of this lncRNA (P = 0.017), and in univariate analyses, higher PCAT6 levels were linked to worse overall survival (OS) (HR = 1.540; 95% CI: 1.079-2.1997; P = 0.017), with this relationship also being preserved in a multivariate analysis (HR = 6.892; 95% CI: 1.713-27.727, P = 0.007). GSEA revealed high PCAT6 expression to be linked to differential DNA methylation enrichment, with high PCAT6 levels being associated with changes in base excision repair, cellular senescence, G2 M DNA damage checkpoint, chromatin-modifying enzyme, and gene silencing by RNA activity. Conclusions: PCAT6 represents a promising prognostic biomarker of poor CRC patient survival outcomes, with DNA methylation and RNA-mediated gene silencing being potentially promising mechanistic pathways whereby this lncRNA may shape patient outcomes.

show abstract

“…Overexpression of lncRNA TUC338 accelerates the tumorigenesis of lung cancer by regulating MAPK pathway [ 30 ]. In addition, the expression of lncRNA PCAT6 is upregulated in a variety of tumors, including hepatocellular carcinoma, ovarian cancer, and NSCLC [ 31–34 ]. Of note, lncRNA PCAT6 (prostate cancer-associated transcript 6) was reported to facilitate the proliferation and invasion of NSCLC cells by regulating miR-330-5p [ 34 ].…”

Section: Introductionmentioning

confidence: 99%

Knockdown of lncRNA PCAT6 suppresses the growth of non-small cell lung cancer cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis

Chen

Hong

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the most common malignant tumor of lung, which seriously threatens the life of people. It has been reported that lncRNA prostate cancer-associated transcript 6 (PCAT6) could facilitate the metastasis of NSCLC cells. However, whether lncRNA PCAT6 in NSCLC cells could affect the tumor microenvironment (TME) remains unclear. In the present study, the level of PCAT6 in NSCLC cells was detected using RT-qPCR. The effects of PCAT6 knockdown on the viability and apoptosis in NSCLC cells were detected with CCK-8 and flow cytometry assay. NSCLC cell-derived exosomes were isolated with ultracentrifugation. Next, transwell assay was conducted to assess the migration and invasion of NSCLC cells. Dual-luciferase reporter assay was performed to verify the relationship among PCAT6, miR-326, and KLF1 in A549 cells. In addition, nanoparticle tracking analysis (NTA) was applied to detect the particle size of isolated exosomes. Moreover, ELISA assay was performed to detect the levels of IL-1β and IL-10 in the supernatant of macrophage. We found knockdown of PCAT6 significantly inhibited the viability, migration, and invasion of NSCLC cells. In addition, dual-luciferase reporter assay illustrated that miR-326 was the target of PCAT6 and KLF1 was the target of miR-326 in NSCLC cells. Moreover, NSCLC cells-derived exosomes could promote macrophages M2 polarization by transporting PCAT6. Meanwhile, macrophages M2 polarization was able to promote the metastasis and epithelial-mesenchymal transition (EMT) process of NSCLC cells via regulating PCAT6/miR-326/KLF1 axis. Taken together, knockdown of lncRNA PCAT6 suppressed the growth of NSCLC cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis.

show abstract

The Role of lncRNA PCAT6 in Cancers

Cited by 16 publications

References 68 publications

Explore the prognostic characteristics of immunogenic cell death- related genes in colon carcinoma based on multi-constraint canonical correlation analysis

Explore the prognostic characteristics of immunogenic cell death- related genes in colon carcinoma based on multi-constraint canonical correlation analysis

LncRNA PCAT6 as a Predictor of Poor Colorectal Cancer Patient Prognosis: A TCGA Dataset Analysis

Knockdown of lncRNA PCAT6 suppresses the growth of non-small cell lung cancer cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis

Contact Info

Product

Resources

About